多糖:阿尔茨海默氏病潜在的生物活性大分子
Gong Peng1, Ming Li2, Zhaoli Meng1
1Laboratory of Tumor Immunology, The First Hospital of Jilin University, Changchun, China.
Frontiers in nutrition
|October 2, 2023
概括
多糖 (PSs) 在治疗阿尔茨海默病 (AD) 方面表现有前途,通过准多种病理途径. 需要进一步进行化学研究,才能充分了解它们在阿尔茨海默病中的治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是导致死亡和残疾的主要原因,目前没有疾病修饰治疗.
- 最近批准的寡曼酸盐突出了糖类在阿尔茨海默病治疗中的潜力.
- 了解糖类在AD病原和治疗中的作用至关重要.
研究的目的:
- 总结和解释多糖 (PSs) 在阿尔茨海默氏症 (AD) 中的作用.
- 审查PSs在缓解AD病理和认知衰退方面的潜在益处.
主要方法:
- 关于多糖和它们在阿尔茨海默病中的影响的最新研究的文献综述.
- 分析PSs可以抵消AD病理的机制.
主要成果:
- 聚糖 (PSs) 在阿尔茨海默氏病的体外和体外都显示出潜在的益处.
- 通过向粉样β和蛋白质,PSs可以减轻病理损伤并改善认知症状.
- 此外,PS还可以减轻氧化压力,减少炎症,促进神经可塑性.
结论:
- 多糖具有解决阿尔茨海默病多种病理方面的潜力.
- 进一步的化学研究是有必要的,以充分阐明PSs在AD的治疗应用.
更多相关视频
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.3K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.0K
相关概念视频
Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Biosynthesis of Polysaccharides
30
Polysaccharides such as glycogen and starch are synthesized from nucleoside diphosphate sugars, primarily uridine diphosphate glucose (UDPG) and adenosine diphosphate glucose (ADPG). These activated glucose donors act as key intermediates in carbohydrate metabolism and biosynthesis. UDPG primarily involves glycogen synthesis in animals and many bacteria, while ADPG plays a fundamental role in starch synthesis in plants and certain bacteria.UDPG is formed when glucose-1-phosphate reacts with...
30
Chemistry of Carbohydrates
72.9K
Carbohydrates are an essential part of the diet in humans and animals. Grains, fruits, and vegetables are natural sources of carbohydrates that provide energy to the body, particularly through glucose, a simple sugar that is a component of starch and an ingredient in many staple foods. The stoichiometric formula (CH2O)n, where n is the number of carbons in the molecule represents carbohydrates. In other words, the ratio of carbon to hydrogen to oxygen is 1:2:1 in carbohydrate molecules. This...
72.9K
Parkinson's Disease: Overview
590
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
590
